Browse recruiting and upcoming clinical trials for IgG4-related disease.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this list Hide ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Sex All Female (includes ALL) Male (includes ALL) All sexes only
Age All ages Pediatric (under 18) Adult (18+)
Clear Who can join AI Adults diagnosed with active Immunoglobulin G4–related disease (IgG4‑RD).
What is being studied AI Compares rilzabrutinib tablets versus placebo for time to IgG4‑RD clinical flare over 52 weeks.
Study type Treatment (drug) · Phase 3
Countries Argentina, Belgium, Canada +16
Who can join AI Adults (18–75) with relapsed or refractory IgG4‑related disease (a B‑cell–mediated autoimmune disorder).
What is being studied AI Tests safety and preliminary efficacy of anti-BCMA‑CD19 CAR‑T cell therapy in IgG4‑RD.
Study type Treatment (drug) · Phase 2
Who can join AI Adults aged 18–75 with active proliferative IgG4-related disease who meet 2019 ACR/EULAR criteria.
What is being studied AI Compares lenalidomide plus prednisone versus prednisone alone for active proliferative IgG4‑RD.
Study type Treatment (drug) · Phase 2/3
Who can join AI People with IgG4‑related disease.
What is being studied AI Tests safety, efficacy, and persistence of ACE1831 cell therapy in IgG4-related disease.
Study type Treatment (drug) · Phase 1/2
Countries China, Japan, United States
Who can join AI Adults 18–65 with relapsed/refractory autoimmune diseases (SLE, systemic sclerosis, inflammatory myopathy, ANCA‑associated vasculitis, antiphospholipid syndrome, rheumatoid arthritis, IgG4‑related disease, or Sjögren's syndrome).
What is being studied AI Tests safety, preliminary efficacy, and PK/PD of a single YTS109 cell infusion.
Study type Treatment (drug) · Phase 1
Who can join AI Adults 18–65 with multiple refractory autoimmune diseases such as SLE, Sjögren, systemic sclerosis, ANCA‑vasculitis, inflammatory myopathy, Behçet, IgG4‑RD, antiphospholipid syndrome, or TTP.
What is being studied AI Tests BCMA-CD19 CAR-T cell therapy for multiple refractory autoimmune diseases.
Study type Treatment (drug) · Phase 2
Who can join AI Adults (≥18 years) with refractory lupus nephritis or refractory IgG4‑related disease.
What is being studied AI Tests safety, dose, and biological effects of PRG-1801 (BCMA-targeting CAR‑T cells) infusion.
Study type Treatment (drug) · Early Phase 1
Who can join AI People with refractory lupus nephritis or refractory IgG4‑related disease.
What is being studied AI Tests safety and dosing of PRG-2311 CAR‑T cells in refractory Lupus Nephritis and IgG4‑RD.
Study type Treatment (drug) · Early Phase 1
Who can join AI People with Behçet's disease, idiopathic inflammatory myopathies (myositis), or IgG4‑related disease.
What is being studied AI Tests daily oral filgotinib for 26 weeks in rare immune-mediated inflammatory diseases.
Study type Treatment (drug) · Phase 2
Who can join AI Adults 18–65 with active, relapsing, or refractory autoimmune kidney diseases (LN, ANCA‑vasculitis, PLA2R+ membranous nephropathy, or IgG4‑related disease).
What is being studied AI Tests FKC289 BCMA/CD19 dual-targeted CAR-T cell therapy for autoimmune kidney diseases.
Study type Treatment (drug) · Phase 1
Who can join AI People with IgG4-related disease (IgG4‑RD) with superficial organ involvement who meet the 2019 ACR/EULAR criteria.
What is being studied AI Compares prednisone+iguratimod versus prednisone+leflunomide for IgG4-RD relapse over 12 months.
Study type Treatment (drug)
Who can join AI Adults with IgG4-related disease or systemic sclerosis (SSc) who have lung involvement.
What is being studied AI Tests safety and tolerability of inhaled UC-EVs and collects early clinical outcome data.
Study type Treatment (drug) · Early Phase 1
Who can join AI People with refractory or recurrent IgG4‑related disease.
What is being studied AI Tests safety, tolerability, and disease activity after a single BCT301 cell infusion.
Study type Treatment (other)
Who can join AI Adults (18–75) with IgG4‑related disease who are in sustained remission after glucocorticoid therapy.
What is being studied AI Tests lenalidomide versus placebo as maintenance therapy to prevent relapse in IgG4-RD.
Study type Treatment (drug) · Phase 3
Who can join AI Adults (18+) with IgG4‑related disease who have a recent or current flare requiring glucocorticoid treatment.
What is being studied AI Tests IMM0306 versus placebo for reducing relapse in IgG4-related disease.
Study type Treatment (drug) · Phase 2/3
Who can join AI Adults aged 18–75 with B-cell–related autoimmune diseases such as SLE, lupus nephritis, MS, myasthenia gravis, IgG4-related disease, or rheumatoid arthritis.
What is being studied AI Tests safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MTM-H-001.
Study type Treatment (drug)
Who can join AI Adults 18–70 with relapsed or refractory active IgG4-related disease who meet accepted diagnostic/classification criteria.
What is being studied AI Tests safety and effects of CD19/BCMA CAR‑NK cell infusions after lymphodepletion in IgG4‑RD.
Study type Treatment (drug) · Early Phase 1
Who can join AI Children ages 2 to <18 years with Immunoglobulin G4-related Disease (IgG4‑RD).
What is being studied AI Tests PK/PD, safety, and tolerability of IV inebilizumab in pediatric IgG4-RD patients.
Study type Treatment (drug) · Phase 2
Countries Brazil, China, Greece +4
Who can join AI Adults (18 years or older) with relapsed or refractory autoimmune diseases including SLE, AIHA, myasthenia gravis, systemic sclerosis, AAV, inflammatory myopathy, or IgG4‑RD.
What is being studied AI Tests a single infusion of universal allogeneic CAR T-cells targeting CD19 and BCMA.
Study type Treatment (drug) · Phase 1
Who can join AI Adults (18–80 years) with active IgG4‑related disease (IgG4‑RD).
What is being studied AI Tests sirolimus plus glucocorticoids for maintenance of remission in IgG4-related disease.
Study type Treatment (drug)
Who can join AI Adults (18+) with fever of unknown origin, IgG4‑related disease, axial spondyloarthritis (axSpA), or inflammation of unknown origin.
What is being studied AI Tests [18F]AlF-FAPI-74 PET/CT versus [18F]FDG PET/CT for detecting and assessing inflammation.
Who can join AI Adults (18–75) with IgG4‑related disease who are in clinical complete remission after glucocorticoid ± immunosuppressant therapy.
What is being studied AI Whether FAPI PET/CT-detected minimal residual disease is linked to IgG4-RD recurrence.
Who can join AI Adults (18+) with active or remitted IgG4-related disease, and healthy adult volunteers.
What is being studied AI Compares blood C5a and C5aR1+ monocytes in IgG4‑RD, remission patients, and healthy controls.
Who can join AI Adults (≥18) undergoing evaluation for suspected autoimmune pancreatitis, including cases where IgG4‑related disease, chronic pancreatitis, or pancreatic cancer are considered in the workup.
What is being studied AI Tests diagnostic accuracy and reproducibility of the Odesa Criteria 2026 (OC26) for autoimmune pancreatitis.
Who can join AI Men aged 50 or older with specified autoimmune, rheumatologic or certain lung conditions, or healthy male controls aged 50+.
What is being studied AI Measures mosaic loss of Y using SNP genotyping, gene expression, cytokine tests, flow cytometry, and routine labs.
Who can join AI Adults 18–75 with newly diagnosed IgG4-related disease who meet the study's diagnostic features and can give informed consent.
What is being studied AI Collects clinical, lab, and imaging data to track disease course and treatment response.
Who can join AI Adults (18–80) with IgG4‑related ophthalmic disease affecting the lacrimal gland, or adults having lacrimal gland ptosis surgery.
What is being studied AI Collects lacrimal gland tissue, blood, and tears to study abnormal T cell activation and differentiation.
Who can join AI People of any age with a clinical or molecular diagnosis of one or more of the listed rare diseases.
What is being studied AI Collects and organizes clinical data to create a single institutional registry for many rare diseases.
Who can join AI Adults with symptoms of adverse reactions to foods or suspected food allergy or intolerance.
What is being studied AI Measures food-specific IgG4 and IgE antibody levels from a small capillary blood sample.
Who can join AI Adults (18–120) with rheumatoid diseases such as rheumatoid arthritis, systemic lupus, systemic sclerosis, IgG4‑related disease, or Sjögren's syndrome.
What is being studied AI Collects and stores blood, synovial fluid and skin biopsies for protein, DNA and RNA extraction.
Who can join AI People diagnosed with IgG4-Related Disease who meet the 2011 comprehensive diagnostic criteria.
What is being studied AI Collects clinical, lab, imaging, pathology, treatment, and outcome data on IgG4-RD patients.
Who can join AI Adults (18+) with autoimmune diseases or certain infectious diseases, their first‑degree relatives, and healthy healthy controls.
What is being studied AI Compares B cell types, function, and autoreactivity between autoimmune, infectious-disease, and healthy groups.